ES2496916T3 - Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas - Google Patents

Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas Download PDF

Info

Publication number
ES2496916T3
ES2496916T3 ES12160109.0T ES12160109T ES2496916T3 ES 2496916 T3 ES2496916 T3 ES 2496916T3 ES 12160109 T ES12160109 T ES 12160109T ES 2496916 T3 ES2496916 T3 ES 2496916T3
Authority
ES
Spain
Prior art keywords
hpv
epitope
til
cells
infiltrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12160109.0T
Other languages
English (en)
Inventor
Sjoerd Henricus Van Der Burg
Gemma G. Kenter
Cornelis Johannes Maria Melief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Application granted granted Critical
Publication of ES2496916T3 publication Critical patent/ES2496916T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Uso de un péptido para la fabricación de un medicamento para el tratamiento de pacientes que sufren o están en riesgo de desarrollar una enfermedad relacionada con el HPV, donde el péptido tiene una longitud que no supera los 100 aminoácidos y comprende al menos 22 aminoácidos contiguos de la secuencia de aminoácidos de una proteína E6 del HPV, donde la secuencia de aminoácidos contigua comprende un epítopo que es presentado por al menos una de una molécula de HLA-DQ y HLADP y donde el epítopo es SEC ID nº: 12, donde la enfermedad relacionada con el HPV se selecciona del grupo que consiste en: neoplasia intraepitelial cervical del cérvix (CIN), vulva (VIN), vagina (VaIN), ano (AIN) y pene (PIN) y cáncer del cérvix, vulva, vagina, ano, pene y cabeza y cuello.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
E12160109
27-08-2014
287 61 carcinosarcom FIGO 2B a 289 45 adeno FIGO 1B 292 32 escamosa FIGO 1B 324 51 escamosa FIGO 1B 353 35 adeno FIGO 1A 373 55 escamosa FIGO 1B 377 85 escamosa FIGO 1B 381 80 adeno FIGO 1B 384 75 escamosa FIGO 1B 414 64 escamosa FIGO 2A CIL 348 35 escamosa CIN3 354 39 escamosa CIN3 LN 426 40 escamosa FIGO 1B
* SI= Índice de estiulación de células T respondedoras
Tabla 2: epítopos de células T reconocidos por pacientes con cáncer cervical Epítopo de tipo de célula T ha reconocido SEC ID de paciente de origen de restricción
Tipo de célula T
Epítopo reconocido Restricción Origen Paciente SEC ID
CD4
HPV16E6.11-32 DP17 LN C148 5
HPV16E6.11-32
DP1401 LN C271,C427 5
HPV16E6.37-68
DP0201 TIL C226 6
HPV16E6.52-61
DP0201 TIL C265 7
HPV16E6.55-86
desconocida LN, TIL C267 8
HPV16E6.61-82
DP1 o DP14 LN C427 9
HPV16E6.73-105
DP4 LN C148 10
HPV16E6 73-105
desconocida LN,TIL C267 10
HPV16E6.91-112
DR15 or DQ5 TIL C331 11
HPV16E6.91-112
desconocida LN C267 11
HPV16E6.101-122
DQ6 LN,TIL C427,C446 12
HPV16E6.121-142
DP0201 o DQ5 TIL C265 13
HPV16E6.121-142
desconocida TIL C187 13
HPV16E6.129-138
DR7 TIL C176 14
HPV16E7.21-42
DR4 TIL C178 15
HPV16E7.51-72
DP1901 CIL C356 16
HPV16E7.76-86
DR12 CIL C284 17
HPV18E6.51-72
DQ*0301 LN C151 18
HPV18E6.71-92
DQ*0501 LN C151 19
HPV18E7.1-32
DQ*0302, DQ*0308 TIL C214 20
HPV18E7.1-32
desconocida TIL C378 20
HPV18E7.21-42
DQ*0302 TIL C228 21
CD8
HPV16E6.13-22 HLA-B7 TIL C446 22
HPV16E6.29-38
HLA-A2 LN C427 23
26

Claims (1)

  1. imagen1
ES12160109.0T 2007-05-31 2008-05-27 Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas Active ES2496916T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US94107007P 2007-05-31 2007-05-31
EP07109281 2007-05-31
EP07109281 2007-05-31
EP07109287 2007-05-31
US941070P 2007-05-31
EP07109287 2007-05-31

Publications (1)

Publication Number Publication Date
ES2496916T3 true ES2496916T3 (es) 2014-09-22

Family

ID=39643924

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08753802T Active ES2411059T3 (es) 2007-05-31 2008-05-27 Epítopos de HPV objetivos de células T que infiltran malignidades cervicales para su uso en vacunas
ES12160109.0T Active ES2496916T3 (es) 2007-05-31 2008-05-27 Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES08753802T Active ES2411059T3 (es) 2007-05-31 2008-05-27 Epítopos de HPV objetivos de células T que infiltran malignidades cervicales para su uso en vacunas

Country Status (8)

Country Link
US (6) US20100189742A1 (es)
EP (4) EP2152729B1 (es)
JP (3) JP6035503B2 (es)
CN (3) CN111686244A (es)
AU (1) AU2008257792B2 (es)
CA (3) CA3167595A1 (es)
ES (2) ES2411059T3 (es)
WO (1) WO2008147187A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA3167595A1 (en) * 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US20110311525A1 (en) * 2008-08-29 2011-12-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
WO2011031298A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
WO2012027365A2 (en) * 2010-08-23 2012-03-01 Selecta Biosciences, Inc. Targeted multi-epitope dosage forms for induction of an immune response to antigens
AU2012249553A1 (en) 2011-04-29 2013-10-24 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
RU2649365C2 (ru) 2012-06-15 2018-04-02 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Вакцинные композиции с катионными липидами и способы применения
MX2015015231A (es) 2013-05-03 2016-07-06 Selecta Biosciences Inc Métodos y composiciones para mejorar las células t reguladoras de cd4+.
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
US10018629B2 (en) 2013-08-08 2018-07-10 Institute Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
JP2016538333A (ja) * 2013-10-13 2016-12-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー ヒトパピローマウイルス治療ワクチン
WO2015184228A1 (en) 2014-05-29 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e7 t cell receptors
KR101677940B1 (ko) * 2014-07-18 2016-11-21 연세대학교 산학협력단 인유두종바이러스 e7 절단된 펩타이드의 자궁경부암 진단 및 치료 용도
EP3201234B1 (en) * 2014-09-30 2018-11-07 Diadem S.r.l. Antibody binding a linear epitope of human p53 and diagnostic applications thereof
EP3253419A1 (en) * 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
EP3058956A1 (en) 2015-02-23 2016-08-24 Institut Curie Combined vaccination/radioterapy for cancer treatment
CA2994965A1 (en) * 2015-08-06 2017-02-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for tumor therapy
CN105131113B (zh) * 2015-08-26 2019-09-06 艾托金生物医药（苏州）有限公司 用于宫颈癌检测和分级的单隆抗体及其应用
EP3377099A4 (en) 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE
AU2017206102C1 (en) 2016-01-08 2022-02-10 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
MY189551A (en) 2016-06-20 2022-02-16 Isa Pharmaceuticals B V Formulation of a peptide vaccine
US9642906B2 (en) * 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
SG11201902988UA (en) * 2016-10-05 2019-05-30 Pds Biotechnology Corp Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
WO2018085751A1 (en) * 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
WO2018102982A1 (zh) * 2016-12-06 2018-06-14 亳州市新健康科技有限公司 一种hpv16型e7蛋白的poct荧光定量检测试剂盒及其应用
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
EP3886886A4 (en) * 2018-11-28 2022-08-24 The General Hospital Corporation T cell-directed anti-cancer vaccines against commensal viruses
WO2020247547A1 (en) * 2019-06-03 2020-12-10 Geovax, Inc. Cancer vaccine compositions and methods for use thereof
US20230087422A1 (en) 2020-02-07 2023-03-23 Isa Pharmaceuticals B.V. Treatment of hpv-related diseases
CN114075293B (zh) * 2020-08-14 2022-11-15 长沙诺盟生物医药有限公司 包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物
MX2023004182A (es) * 2020-10-15 2023-06-22 Aavocyte Inc Vectores de virus adenoasociados recombinantes con promotor de cumulo de diferenciacion 14 (cd14) y uso de los mismos.
CN115433713B (zh) * 2022-03-03 2023-10-27 中山大学孙逸仙纪念医院深汕中心医院 一种自体肿瘤引流淋巴结淋巴细胞的制备方法及其应用
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US182763A (en) * 1876-10-03 Improvement in cow-milkers
PT97073A (pt) * 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
EP0523391B1 (en) 1991-07-13 2003-03-19 Dade Behring Marburg GmbH Use of HPV-16 E6 and E7-gene derived peptides for the diagnostic purpose
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
DE19737409A1 (de) * 1997-08-27 1999-03-04 Medigene Ag Diagnosekit für Hauttest und Verfahren zur Durchführung desselben
ATE304375T1 (de) 1998-05-23 2005-09-15 Univ Leiden Medical Ct Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
GB9921938D0 (en) * 1999-09-17 1999-11-17 Univ York Target for antiviral therapy
DE10059631A1 (de) * 2000-12-01 2002-07-18 Medigene Ag T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie
JP2004525115A (ja) * 2000-12-08 2004-08-19 アカデミス ツィーケンホイス ライデン 抗原特異的免疫応答を誘起及び／又は増強する、２２〜４５アミノ酸残基からなる長いペプチド
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
WO2002100889A1 (fr) * 2001-06-08 2002-12-19 Kirin Beer Kabushiki Kaisha Nouvel epitope de l'antigene e7 du papillomavirus humain et lymphocytes t cd4 positifs actives par l'epitope
US7410758B2 (en) * 2001-07-20 2008-08-12 Board Of Regents, The University Of Texas System Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
US20070037151A1 (en) * 2003-04-28 2007-02-15 Babe Lilia M Cd4+ human papillomavirus (hpv) epitopes
JP5030594B2 (ja) * 2003-12-23 2012-09-19 アルボー ビータ コーポレーション Ｈｐｖの発癌性株に対する抗体およびそれらの使用方法
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
CA2552508A1 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2005070959A2 (en) * 2004-01-23 2005-08-04 Vievax Corp. Compositions comprising immune response altering agents and methods of use
ES2293178T3 (es) * 2004-03-18 2008-03-16 Institut Pasteur Proteina recombinante que contiene epitopos del papilomavirus humano insertados en un proteina adenilato ciclasa o un fragmento de la misma y usos terapeuticos de la misma.
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
ES2482192T3 (es) * 2007-05-31 2014-08-01 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacunación intradérmica del péptido de HPV
CA3167595A1 (en) * 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof

Also Published As

Publication number Publication date
CA2692652C (en) 2018-10-23
EP3584251A2 (en) 2019-12-25
CA3016942C (en) 2022-09-20
CN101765607A (zh) 2010-06-30
EP2468763B1 (en) 2014-06-18
JP6035503B2 (ja) 2016-11-30
EP3584251A3 (en) 2020-01-29
US20100189742A1 (en) 2010-07-29
CA2692652A1 (en) 2008-12-04
EP2757109A2 (en) 2014-07-23
US11458198B2 (en) 2022-10-04
CN111686244A (zh) 2020-09-22
JP6146879B2 (ja) 2017-06-14
CN105031610A (zh) 2015-11-11
US20150056234A1 (en) 2015-02-26
US20230256075A1 (en) 2023-08-17
JP2015147786A (ja) 2015-08-20
CN105031610B (zh) 2020-06-19
CA3016942A1 (en) 2008-12-04
EP2757109B1 (en) 2019-07-10
EP2468763A2 (en) 2012-06-27
JP2010527630A (ja) 2010-08-19
US9764023B2 (en) 2017-09-19
AU2008257792B2 (en) 2013-08-29
EP2468763A3 (en) 2012-07-04
WO2008147187A1 (en) 2008-12-04
US20190184002A1 (en) 2019-06-20
JP6312886B2 (ja) 2018-04-18
US20200289640A1 (en) 2020-09-17
CN101765607B (zh) 2015-09-09
EP2152729B1 (en) 2013-03-20
US10688173B2 (en) 2020-06-23
US10258684B2 (en) 2019-04-16
CA3167595A1 (en) 2008-12-04
US20170348410A1 (en) 2017-12-07
JP2017137333A (ja) 2017-08-10
ES2411059T3 (es) 2013-07-04
EP2757109A3 (en) 2014-09-03
EP2152729A1 (en) 2010-02-17
AU2008257792A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
ES2496916T3 (es) Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas
CA2886631C (en) Pam3cys-like lipopeptide adjuvant compound in a vaccine composition
US6380157B1 (en) Method of treatment using papillomavirus L2 protein
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
Peng et al. Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells
ES2371006T3 (es) Procedimiento para el tratamiento del cáncer de cuello de útero.
KR20100019432A (ko) 다중 유전자 발현용 벡터
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
KR101515445B1 (ko) 세포 투과 펩타이드 및 치료 작용을 갖는 생체 분자에 결합된 이의 용도
Yang et al. Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination
US20100143395A1 (en) Material with immunogenicity
GB0417430D0 (en) A novel HPV vaccine comprising peptides from host cell proteins
Noël et al. Transformation of common warts into squamous cell carcinoma on sun-exposed areas in an immunosuppressed patient
JP5964298B2 (ja) ヒトパピローマウイルスｅ７抗原組成物およびその使用
Kumar et al. Pituitary cachexia after rabies encephalitis
Reuter et al. Optimization of cottontail rabbit papilloma virus challenge technique
ES2232018T3 (es) Kit de diagnostico para prueba y procedimiento para llevar a cabo la misma.
Sánchez-García et al. Epidermodisplasia verruciforme
CN1372598A (zh) 诱导细胞死亡的方法
RU2008106481A (ru) Композиция для лечения и предупреждения папилломавирусной инфекции человека на основе белка l1 и пептидов белка е7
AU2013205259A1 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines